PYCXF Stock Chart & Stats
$1.66
$0.02(1.77%)
At close: 4:00 PM EDT
$1.66
$0.02(1.77%)
Day’s Range― - ―
52-Week Range$0.70 - $2.05
Previous CloseN/A
Volume500.00
Average Volume (3M)849.00
Market Cap
$1.30B
Enterprise Value$1.21B
Total Cash (Recent Filing)$447.56M
Total Debt (Recent Filing)$624.99K
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Mar 01, 2027EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding984,750,400
10 Day Avg. Volume2,042
30 Day Avg. Volume849
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-27.48
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.01K
Enterprise Value/Ebitda-14.86
Forecast
1Y Price Target
$2.74Price Target Upside65.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt relative to equity gives PYC a stronger solvency base than a highly leveraged development biotech. This reduces balance-sheet pressure while the company funds its pipeline, although it does not yet solve the lack of profitability.
Proprietary RNA PlatformsProprietary discovery and delivery platforms may provide a differentiated foundation for developing RNA therapeutics across diseases with high unmet medical need. If successfully translated into clinical products, these capabilities could support a broader and more defensible pipeline.
Capital And Equity GrowthSubstantial growth in assets and equity indicates that PYC has secured capital to support ongoing development activities and maintain liquidity. This provides near-term balance-sheet capacity for advancing its pipeline, even though future funding needs remain material.
Bears Say
Persistent Operating LossesPersistent large losses show that PYC has not yet converted its research and development activities into a profitable operating model. Continued losses can constrain internally funded growth and make future value creation dependent on successful clinical and commercial execution.
Negative Cash GenerationOngoing negative operating and free cash flow means the business is not self-funding its development program. Accelerating burn increases reliance on external financing, creating a durable funding risk if capital markets or investor support become less available.
Revenue VolatilityThe fall from meaningful prior revenue to zero in FY2026 highlights substantial uncertainty in PYC’s revenue base and commercialization progress. With operating expenses still overwhelming gross profit when revenue exists, the company lacks a stable earnings foundation.
PYC Therapeutics Limited News
PYCXF FAQ
What was PYC Therapeutics Limited’s price range in the past 12 months?
PYC Therapeutics Limited lowest stock price was $0.70 and its highest was $2.05 in the past 12 months.
What is PYC Therapeutics Limited’s market cap?
PYC Therapeutics Limited’s market cap is $1.30B.
When is PYC Therapeutics Limited’s upcoming earnings report date?
PYC Therapeutics Limited’s upcoming earnings report date is Mar 01, 2027 which is in 121 days.
How were PYC Therapeutics Limited’s earnings last quarter?
PYC Therapeutics Limited released its earnings results on Aug 28, 2026. The company reported -$0.016 earnings per share for the quarter, beating the consensus estimate of -$0.018 by $0.001.
Is PYC Therapeutics Limited overvalued?
According to Wall Street analysts PYC Therapeutics Limited’s price is currently Undervalued.
Does PYC Therapeutics Limited pay dividends?
PYC Therapeutics Limited does not currently pay dividends.
What is PYC Therapeutics Limited’s EPS estimate?
PYC Therapeutics Limited’s EPS estimate is -0.02.
How many shares outstanding does PYC Therapeutics Limited have?
PYC Therapeutics Limited has 984,750,400 shares outstanding.
What happened to PYC Therapeutics Limited’s price movement after its last earnings report?
PYC Therapeutics Limited reported an EPS of -$0.016 in its last earnings report, beating expectations of -$0.018. Following the earnings report the stock price went down -2.439%.
Which hedge fund is a major shareholder of PYC Therapeutics Limited?
Currently, no hedge funds are holding shares in PYCXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PYC Therapeutics Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.74 (65.05% Upside)
$2.74 (65.05% Upside)
Blogger Sentiment
Bullish
PYCXF Sentiment 100%
Sector Average 64%
Sector Average 64%
Insider Transactions
Bought Shares
Worth $142.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.48%
12-Months-Change
Fundamentals
Return on Equity
-10.31%
Trailing 12-Months
Asset Growth
286.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
PYC Therapeutics Limited
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
PYCXF Stock 12 Month Forecast
Average Price Target
$2.74
▲(65.05% Upside)
Technical Analysis
Ownership Overview
0.07% Insiders
0.19% Mutual Funds
<0.01% Other Institutional Investors
96.83% Public Companies and
Individual Investors